Schedule an Appointment
Resverlogix Corp.

Resverlogix Corp.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Resverlogix Corp.

Location: Calgary, Alberta Sector: Life Science .
Add to Shortlist
Express Interest

Resverlogix Corp. is a Calgary and San Francisco based clinical stage biotechnology company focused primarily on the development of apabetalone. Apabetalone (RVX 208) is a first-in-class small molecule selective BET bromodomain inhibitor, which acts via an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high risk CVD patients with type 2 DM and low high density lipoprotein (HOL) and is expected to be initiated in a Phase 2a kidney dialysis trial.

Business Documents

MG cp Summary

Late Stage Human Clinical Trials  – Resverlogix is focused on significant unmet need in high-risk CVD, diabetes and CKD patient populations, with a phase 3 human clinical trial (BETonMACE) in high risk CVD.

 

Advanced R&D – Resverlogix’s in-depth understanding of BET inhibitors and world-class medicinal chemistry allows it to develop candidates with better specificity, which affords the opportunity to target chronic disease through the BET pathway.

 

Market Leader Targeting Significant Unmet Need – Apabetalone is expected to be indicated in several high-risk patient groups totaling over 10M patients in the top seven markets (US, 5EU and Japan).

 

Established Safety Profile – Over 1,400 patients have been treated to date with apabetalone with no significant safety issues.

 

Novel Mechanism of Action – Regulation of gene transcription, the turning on or off of various disease-causing genes (unlike the CRISPR approach of changing DNA).

 

Quality Investor Base – Proven track record of attracting high quality and long term institutional investors

Resverlogix is developing apabetalone, its lead compound, and other compounds that specifically bind the bromodomains of BET proteins. In binding to these bromodomains, these compounds affect the expression of multiple genes with roles in multiple cellular processes that underlie disease. Apabetalone, is currently in phase 3 human clinical trials in 13 countries worldwide and Resverlogix’s platform features other promising follow-on compounds.

 

Utilizing its knowledge of BET proteins and epigenetics, Resverlogix has identified small molecule candidates with the following characteristics:
–Function via selective inhibition of BET proteins
–Alter the activity of genes that play a key role in disease in relevant cell models
–Demonstrated preclinical and clinical activity against disease targets

 

 

DONALD J. MCCAFFREY, President & CEO/Co-Founder

Co-founder, strategic leader and organizational mentor of the company
Over 35 years of business experience including 18 years of drug discovery & development
Personally raised over $300 million for research and clinical development in the areas of CVD, diabetes, CKD, orphan diseases and other indications of high unmet need

 

DR. EWELINA KULIKOWSKI, Ph.D, Senior Vice President of Research & Development

Over 12 years experience in scientific research and drug development
Involved in the development of apabetalone (RVX-208) from its discovery through to the IND and into clinical development
Doctorate in Oncology from the University of Calgary in 2004

 

DR. MICHAEL SWEENEY, MD, Senior Vice President of Clinical Development

Over 26 years in the pharmaceutical industry
11 years at Pfizer Inc
CMO and VP of Research and Development at Depomed
VP Medical Affairs at CV Therapeutics, Inc

 

DR. ELDON R. SMITH, OC, MD, FRCPC, FCAHS, FAHA, FIACS Board of Directors Lead Director

Published more than 250 papers and book chapters
Former Dean of the Faculty of Medicine at the University of Calgary
Former Editor-in-Chief of the Canadian Journal of Cardiology
Past President of the Canadian Cardiovascular Society and the Association of Canadian Medical Colleges, Vice President of the Inter-American Society of Cardiology.


S2G Biochemicals Inc.

S2G Biochemicals Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

Book a Conference Call
Get More Information

S2G Biochemicals Inc.

Location: Vancouver, British Columbia Sector: Life Science .
Add to Shortlist
Express Interest

s2G Biochemicals Inc. has developed the most sustainable and lowest cost technology to co-produce xylitol – a premium low-calorie sweetener – and biochemical glycols. Xylitol is a natural sweetener with the same sweetness quality as regular sugar, but 1/5 the glycemic index effect (1/5 the effect on blood sugar levels) and 40% less calories than regular sugar. It is safe for consumption by people who have intolerance to regular sugar for diabetic or dietary reasons. Valued for its excellent taste and oral health benefits, xylitol produced with S2G technology will enjoy strong growth in the multi-billion dollar low-calorie sweetener market.

Business Documents

MG cp Summary

Sustainable – Most sustainable production process technology:  High yield, no harsh chemicals and supports shift away from reliance on oil and gas.

 

Cost effective – Most cost-effective production methods- S2G technology makes xylitol at lowest cost while producing high value bio-glycols.

 

Valuable co-products – No other production methods produce viable quantities of valuable co-products; S2G produces bio-glycols which adds to overall returns for plants employing the S2G technology.

 

Non-GMO – S2G’s process for producing xylitol includes sources of feedstocks that are non-GMO – a feature of growing importance for consumers. S2G intends to only produce using non-GMO sources.

 

Pulp mill/biorefinery value-add – S2G’s process uses sustainable byproducts produced by various pulp mills and biorefineries from biomass (agriculture and forest residues).  These experienced operators are diligently looking for new sources of income to increase their revenues and add value to their current production. Presently they are unable to get more than heating value from the bioproducts of their pulping processes.  The S2G Xylitol process will increase byproduct value from ~$125/MT to ~$2000/MT.

S2G Biochemicals Inc. has developed the most sustainable and lowest cost technology to co-produce xylitol – a premium low-calorie sweetener – and biochemical glycols. Xylitol is a natural sweetener with the same sweetness quality as regular sugar, but 1/5 the glycemic index effect (1/5 the effect on blood sugar levels) and 40% less calories than regular sugar. It is safe for consumption by people who have intolerance to regular sugar for diabetic or dietary reasons. Valued for its excellent taste and oral health benefits, xylitol produced with S2G technology will enjoy strong growth in the multi-billion dollar low-calorie sweetener market.

Mark Kirby – President and CEO |  Mark is a chemical industry and cleantech Executive with a strong leadership, business developement, engineering, operations and product development background. He has attained success with both major multinational corporations and with technology start-up companies.

 

Jeff Plato – Director, Corporate and Project Development | Jeff has 30+ years of growth leadership in business unit, technology and services sales and marketing management. He bring extensive leadership , sales and marketing management experience in electronic, industrial and clean energy industries to S2G.

 

Himanshu Kamboj – CFO | A graduate of the University of British Columbia, Himanshu assumed roles accounting roles and management positions at Dale Matheson Carr-Hilton Labonte Chartered Accountants and MNP LLP before joining S2G where he heads the accounting, tax and finance departments. He also maintains investor relations and is in charge of audits.

 

Kent Smith – Director, Projects | Kent is a senior manager/executive/professional engineer with over 20 years of experience in port operations, maintenance, mining, procurement, logistics and business management. Prior to joining S2G biochemicals, Kent worked at SRK Engineering Limited, Pacific coast terminals co. and Vancouver Wharves Ltd.

 

Claudio Arato – Senior Engineer, Director, Process | Caludio lead the process team at S2G on $5.5MM pilot plant scale up and the development team on catalytic process of converting C3 and C5/C6 sugars to glycols.  Before S2G, Caludio worked in various capacities including CTO, Director of engineering and technology, and senior engineer in companies that include Provectus Engineered Materials, Sonoro Energy and Lignol Innovations.


Biopep Solutions Inc.

Biopep Solutions Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Biopep Solutions Inc.

Location: Richmond, British Columbia

Sector: Life Science

.

Add to Shortlist
Express Interest

Biopep Solutions Inc. is a private late-preclinical stage bio-tech company. Biopep’s lead candidate drug’s multivalent cancer inhibition mechanism is revolutionary in the treatment of cancer. The drug, called BPS-001, blocks the channels cancer tumors use to promote cancer survival  and their ability to grow and spread.  Rather than being limited to the short-comings of current drugs and therapies, Biopep believes that it is developing the next generation of cancer therapy that will simultaneously block the different channels of cancer growth.

Business Documents

MG cp Summary

Need for a drug that is effective against cancer resistance 

The problem with conventional drugs and therapies is that the cancer develops resistance to them over time and it returns in a more aggressive form.In comparison to the weaknesses of the current prostate cancer drugs, BPS-001 inhibits the expression of the entire androgen receptor as well as inhibiting the growth of new blood vessels, reducing inflammation and cancer cell migration, and activating cancer cell death.

 

Need for a cancer therapy with minimal side effects

Chemotherapy is toxic and has a negative impact on the quality of life for the patient. As well as being toxic, it is non-specific, meaning healthy cells are also affected. BPS-001 is non-toxic at over 160 times the normal dose in animal studies. As opposed to conventional cancer therapies, BPS-001 is administered weekly through an injection similar to insulin.

 

Need for effective late stage prostate cancer therapy

When caught early, prostate cancer is often treatable. However, the only option to advanced prostate cancer patients treatment is chemotherapy which is very toxic and only prolongs life.BPS-001 has the potential to change the landscape of cancer therapy by providing a more effective treatment of late stage metastatic prostate cancer (mCRPC) in comparison to existing drugs, without any significant toxic side effects, and durable treatment.

Biopep’s lead drug candidate, BPS-001, has a unique multivalent mechanism to treat various forms of cancer.  The initial target indication is prostate cancer.  However, unlike conventional therapies like chemotherapy, hormone depravation therapy or immunotherapy, BPS-001 has the following advantages:

  • A multivalent mechanism of action, which targets multiple pathways and sites on the cancer cell, which means the cancer will be unable to develop resistance to the treatment which is the case with conventional single targeted drugs;
  • Inhibits the formation of new blood vessels that feed the cancer (i.e. inhibits the process of angiogenesis);
  • Promotes the programmed death of cancer cells by a process called apoptosis;
  • Reduces inflammation which is a driver of all major diseases;
  • BPS-001 has very low toxicity giving it a large therapeutic window;
  • Ease of administration, a once weekly subcutaneous injection; and
  • BPS-001 has the potential to change the landscape of cancer therapy by providing a more effective treatment for late stage prostate cancer (mCRPC) in comparison to existing drugs and therapies.

Ahmed Merzouk, Director, President and Chief Executive Officer

Dr. Merzouk has more than 20 years’ experience in industry and academia in drug discovery of small and large molecules. The expertise of Dr. Merzouk ranges from design, synthesis, and purification of synthetic molecules to extraction of active ingredients from natural sources.

 

Yalcin Ilsever, PhD, CPA.CGA, IMA(USA),FICBDirector, Executive Vice President and Chief Financial Officer

Dr. Ilsever is a Chartered Professional Accountant (CPA). His PhD is in  Accounting, Finance and Statistical Measurement. He has extensive experience in the private sector in the issuance of fixed income securities and equities. Dr. Ilsever has also published extensively on electronic commerce platforms, and business measurement systems.

 

Gary Yalloway, PhD, Director, Vice President, Regulatory Affairs and Drug Development

Dr. Yalloway has over 22 years of multidisciplinary experience in industry and academia and skills in enzyme engineering and protein purification of proteins of medical and industrial interest. He has significant experience in regulatory affairs with both the US Food and Drug Administration and Health Canada. He is highly experienced in all aspects of R&D, process development, and the scale-up and manufacture of therapeutic proteins. His specialties include upstream and downstream processing, including large-scale production and bulk manufacturing of recombinant proteins.


Aquila Diagnostic Systems

Aquila Diagnostic Systems

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Aquila Diagnostic Systems Inc.

Location: Edmonton, Alberta

Sector: Life Science

.

Add to Shortlist
Express Interest

Aquila Diagnostic Systems Inc. is exploiting its patented molecular (DNA/RNA) diagnostic technology to provide a game-changing solution for the tangible and quantifiable pain caused by the poor state of diagnostics which currently exists in the large North American and European markets for companion animal (canine and feline), with plans to expand to the equine and food production markets including poultry, dairy and porcine.

Business Documents

MG cp Summary

Low cost technology – Ability to price Aquila products at same price as veterinarians pay today for an inferior product

 

Ability to work with any industry standard diagnostic instrument – Aquila is not building a diagnostic instrument: we are agnostic to instrument providing the customer with a wide variety of instrument options depending upon budget and requirements.

 

Patents on Aquila hydrogelStrong patents in place in a technology where such patents are extremely difficult to achieve

 

Ability to work with “dirty” samples – Aquila’s patented hydrogel provides a significant and sustainable competitive advantage with its unmatched ability to work with “dirty” samples such as milk and feces.

 

Simple or no DNA extraction required from sample – Minimizes or eliminates step when compared to conventional PCR technology. Lowers cost and time to perform test.

“ Aquila Diagnostic Systems Inc. is exploiting its patented molecular (DNA/RNA) diagnostic technology to provide a game-changing solution for the tangible and quantifiable pain caused by the poor state of diagnostics which currently exists in the large North American and European markets for companion animal (canine and feline), with plans to expand to the equine and food production markets including poultry, dairy and porcine.”

Brent James, CEO, B.Comm UBC; MBA Sloan School MIT

Brent James has a 30-year history of accomplishments in the high tech field including co-founding a company (MDSI) that went public on NASDAQ, and being the turn-around CEO of a company (Abebooks.com), which was sold to Amazon.

 

Dr. Jason Acker, Co-Founder & CTO; BSc, MSc, MBA, PhD

Dr.Jason Acker, Co-Founder and Chief Technology Officer, brings more than 15 years of experience with multinational pharmaceutical and biotechnology companies in Canada, USA, Singapore and the U.K.  Jason also managed interdisciplinary teams at the University of Alberta, Canadian Blood Services, and Harvard Medical School.

 

David Alton, Co-Founder & COO; MBA

David Alton co-Founder and Chief Operating Officer of Aquila, has extensive experience in the micro and nano technology sectors, research management and company start-ups

 


PlantForm Corporation

PlantForm Corporation

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

PlantForm Corporation

Location: Toronto, Ontario

Sector: Life Science

.

Add to Shortlist
Express Interest

PlantForm Corporation is a privately-held Canadian biopharmaceutical company, commercializing a plant-based manufacturing platform, vivoXPRESS®, for the low-cost production of high-value therapeutic drugs. Their pipeline includes biosimilar drugs with a focus on international markets including China, Europe, India, Latin America, MENA as well as major North American and European markets. The company is also developing innovator biologics for niche infectious disease and countermeasures-to-bioterrorism markets. Their pipeline is funded through equity, government grants and contracts from non-profit organizations, such as the Bill & Melinda Gates Foundation.

Business Documents

MG cp Summary

Patented production system (vivoXPRESS®) – The plant based production system produces high quality drugs at very low cost.

 

Unique glycosylation of drugs – Protein and antibody molecules often have carbohydrates (sugars) decorating the surface. PlantForm can create unique structures increasing the efficacy and reducing the dose such protein and antibody drugs.

 

Experienced management team – Veterans in the biotechnology industry having the experience to move the high-value PlantForm investment proposition forward.

PlantForm Corporation is a privately-held Canadian biopharmaceutical company, commercializing a plant-based manufacturing platform, vivoXPRESS®, for the low-cost production of high-value therapeutic drugs. Their pipeline includes biosimilar drugs with a focus on international markets including China, Europe, India, Latin America, MENA as well as major North American and European markets. The company is also developing innovator biologics for niche infectious disease and countermeasures-to-bioterrorism markets. Their pipeline is funded through equity, government grants and contracts from non-profit organizations, such as the Bill & Melinda Gates Foundation.

Don Stewart, CEO

Dr. Don Stewart, an entrepreneur and scientist, is a founder of PlantForm and assumes the roles of President and Chief Executive Officer.  Dr. Stewart brings 30 years’ management experience in the biotechnology industry to this role.  Dr. Stewart has founded and developed companies in the field of biotechnology and in real estate.

 

Ron Hosking, CFO

Mr. Ron Hosking, an experienced financial manager and chartered accountant, is a founder of PlantForm Corporation. Mr. Hosking brings 35 years of experience, providing strong leadership, sound business management and clear strategic financial direction to growing businesses in the life sciences industry.

 

David Cayea, COO

Mr. David Cayea is an entrepreneur who has successfully launched private-sector companies in multiple industries over the last 20 years.  Mr. Cayea joined PlantForm in 2011 as Director of International Relations & Business Development, responsible for advancing the Companies strategic growth strategy by developing and fostering global partnerships. More recently Mr Cayea was appointed to the expanded role of COO of PlantForm.